Combination Therapy Achieves 15-Month Progression-Free Survival in Advanced Large-Cell Neuroendocrine Lung Carcinoma
Key Insights
A 58-year-old male patient with advanced large-cell neuroendocrine lung carcinoma (search) achieved a partial response and 15.1 months progression-free survival after treatment with sovantinib (search) combined with toripalimab following chemotherapy failure.
The patient had high tumor mutational burden (17.5-25 mut/Mb) despite negative PD-L1 (search) expression, which correlated with sustained response to immune checkpoint inhibitor therapy.
Dynamic monitoring of the immune microenvironment showed increased cytotoxic immune cells during effective treatment periods, followed by decreased activity corresponding to disease progression.
A 58-year-old male patient with advanced large-cell neuroendocrine lung carcinoma (search) (LCNEC (search)) achieved remarkable clinical outcomes with combination targeted immunotherapy, demonstrating the potential for personalized treatment approaches in this rare and aggressive malignancy.
The patient initially presented in February 2022 with left lung LCNEC (search), stage cT1N2M1aIVA. After six cycles of first-line etoposide plus carboplatin (EP) chemotherapy, the disease progressed, leading to treatment with second-line FOLFIRI (search) chemotherapy. However, progressive disease was observed after four cycles, with target lesions increasing from 7.5 cm to 9.3 cm.
Breakthrough Response with Combination Therapy
In November 2022, the patient was enrolled in a randomized phase III clinical trial evaluating sovantinib (search) combined with toripalimab versus FOLFIRI (search) as second-line treatment for advanced neuroendocrine carcinoma (search). Treatment with sovantinib plus toripalimab resulted in a partial response, with the left lung mass decreasing from 9.3 cm to 7.9 cm after three cycles, representing a 15% reduction and stable disease evaluation.
The combination therapy demonstrated sustained efficacy over an extended period. By August 2023, imaging revealed continued tumor shrinkage with a 31% reduction, maintaining partial response status. The patient achieved progression-free survival of 15.1 months before disease progression was detected in February 2024.
Biomarker-Guided Treatment Success
Genetic analysis revealed key factors contributing to the treatment response. Despite negative PD-L1 (search) expression, the patient exhibited high tumor mutational burden (TMB), with levels of 17.5 mut/Mb initially and 25 mut/Mb at follow-up testing. This TMB-high status correlated with the sustained response to immune checkpoint inhibitor therapy.
Dynamic monitoring of gene mutations during treatment showed stable or declining mutation abundance levels, with significant differences observed between pre- and post-treatment samples (P=0.0006). The high TMB provided a strong rationale for the effectiveness of the immunotherapy combination.
Immune Microenvironment Dynamics
Comprehensive analysis of the tumor immune microenvironment revealed correlations between treatment efficacy and immune cell populations. During effective treatment periods, the number of cells with cytotoxic or anti-tumor effects in both tumor parenchyma and stroma significantly increased. Conversely, when disease progression occurred, these beneficial immune cell populations decreased while immunosuppressive cells became more prevalent.
Peripheral blood analysis showed T lymphocytes were highly expressed in the early stages of targeted immunotherapy and then gradually decreased, suggesting tumor-specific T cell activation following PD-1 (search) inhibitor application. This pattern aligned with the clinical response timeline.
Treatment Evolution and Continued Benefit
Following disease progression in February 2024, the patient received two cycles of EP chemotherapy, but progressive disease continued with new bone metastases. The treatment regimen was then switched to everolimus combined with toripalimab plus denosumab for bone protection.
After three cycles of the new combination, imaging evaluation in July 2024 showed stable disease with a 21.4% reduction in tumor size. The patient's overall survival has exceeded 33 months from initial diagnosis, demonstrating the potential for sequential targeted immunotherapy approaches.
Clinical Implications for LCNEC Treatment
LCNEC (search) represents approximately 3% of all lung cancers and carries a poor prognosis, with 5-year overall survival rates of only 21%. Current treatment options are limited, with chemotherapy providing median progression-free survival of only 5-6 months and overall survival of 7.7-12.6 months.
This case highlights the importance of biomarker testing in LCNEC (search) patients. While PD-L1 (search) expression was negative, the high TMB status predicted response to immune checkpoint inhibitor therapy. The combination of sovantinib (search), a multi-kinase inhibitor targeting VEGFR (search) 1-3, FGFR 1, and CSF-1R (search), with toripalimab, a PD-1 (search) antibody, demonstrated synergistic anti-tumor effects.
Previous studies have shown that LCNEC (search) patients have higher TMB levels than other neuroendocrine tumors, supporting the potential for immunotherapy in selected patients. A retrospective analysis revealed median overall survival of 23.5 months versus 11.2 months for LCNEC patients treated with versus without immune checkpoint inhibitors.
Mechanistic Insights
The success of the combination therapy appears related to sovantinib (search)'s dual mechanisms of action. By inhibiting angiogenesis through VEGFR (search) blockade and modulating the immune microenvironment through CSF-1R (search) inhibition, sovantinib reduces M2-type tumor-associated macrophages and enhances immune cell infiltration. This creates a more favorable environment for toripalimab's anti-PD-1 (search) activity.
The case demonstrates that targeted immunotherapy combinations can achieve meaningful clinical benefit in TMB-high LCNEC (search) patients, suggesting that immune microenvironment analysis may facilitate personalized treatment approaches. Future research should focus on identifying optimal biomarkers to select patients most likely to benefit from these combination strategies.